Upregulation of BTF3 affects the proliferation, apoptosis, and cell cycle regulation in hypopharyngeal squamous cell carcinoma - 18/09/19
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 8 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
The expression of BTF3 is overexpressed in HSCC and is associated with lymph node metastasis and survival. Our in vitro and in vivo experiments have shown that BTF3 knockdown significantly impaired regulation of proliferation, cell cycle, and apoptosis, potentially via ATM signaling pathway and demonstrated that BTF3 functioned as an oncogene in the development and progression of HSCC tumors.
Le texte complet de cet article est disponible en PDF.Highlights |
• | BTF3 is upregulated in HSCC compared with adjacent normal tissues. |
• | BTF3 expression is significantly associated with advanced disease stage and survival. |
• | In vitro experiments indicate BTF3 affects proliferation, cell cycle and apoptosis via ATM pathway. |
• | In vivo experiments support an oncogenic role of BTF3 in progression and development of HSCC. |
Abstract |
Purpose |
The BTF3 is involved in oncogenesis, while the biological roles in HSCC remain unclear. The aim of this study was to explore the impact of BTF3 knockdown on biological phenotypes of human HSCC in vivo and in vitro.
Methods |
The expression of BTF3 was assessed in HSCC and normal tissues. In vitro experiments were performed to explore impact of BTF3 knockdown on biological phenotypes of human HSCC cell line, including proliferation, cell cycle, and apoptosis. Moreover, nude mice were used to evaluate growth of xenograft tumors. Finally, gene chip was used to explore the potential signaling pathways of BTF3, with confirmation of potential BTF3-related genes.
Results |
Our results showed elevated expression of BTF3 was observed in HSCC tumors compared to paired adjacent normal tissues in 68 patients, and positively associated with lymph node metastasis and survival of this HSCC patient cohort. In addition, in vitro experiments showed that BTF3 knockdown significantly impaired regulation of proliferation, cell cycle, and apoptosis, potentially via ATM signaling pathway. Finally, in vivo experiments demonstrated that BTF3 functioned as an oncogene by promoting the development and progression of HSCC tumors, indicating its oncogenic role in HSCC.
Conclusions |
This study for the first time demonstrated that expression of BTF3 is upregulated in HSCC tumors and this upregulation is positively correlated with lymph node metastasis of this malignancy. The oncogenic role of BTF3 is further validated for tumor promotion and progression of HSCC in vivo, indicating that BTF3 is a potential therapeutic target and prognostic biomarker for HSCC.
Le texte complet de cet article est disponible en PDF.Abbreviations : BTF3, HSCC, CRISPR/Cas9
Keywords : BTF3, HSCC, CRISPR/Cas9, Knockout
Plan
Vol 118
Article 109211- octobre 2019 Retour au numéro
Article précédent
- 4-XL-PPD, a novel ginsenoside derivative, as potential therapeutic agents for gastric cancer shows anti-cancer activity via inducing cell apoptosis medicated generation of reactive oxygen species and inhibiting migratory and invasive
- Xu De Wang, Yuan Yuan Sun, Fan Zhi Qu, Guang Yue Su, Yu Qing Zhao
- FALEC exerts oncogenic properties to regulate cell proliferation and cell-cycle in endometrial cancer
- Qing-Hong Zheng, Lei Shi, Hua-Li Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?